Clinic Visits for Opioid Safety

N/A

Waitlist Available

Research Sponsored by Kaiser Permanente

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients prescribed Chronic Opioid Therapy

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up outcomes are assessed in a two-month post-intervention period.

Awards & highlights

No Placebo-Only Group

Summary

This trial will look at how a special clinic can help patients who are taking opioids for a long time. The study will see if going to this clinic affects how often patients visit, get naloxone

Who is the study for?

This trial is for patients on chronic opioid therapy. It's designed to see if an opioid safety clinic can help them use opioids more safely. The study will track how often they visit the clinic, get naloxone (a drug that reverses overdoses), check their prescriptions, and do urine tests.

What is being tested?

The 'MHC Outreach Intervention' is being tested to promote safe use of opioids among patients who take these drugs regularly. The intervention includes visits to a special clinic focused on opioid safety.

What are the potential side effects?

Since this trial focuses on an outreach intervention rather than a medication, traditional side effects are not applicable. However, there may be indirect effects from changes in how participants manage their opioid medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am on long-term opioid medication.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ outcomes are assessed in a two-month post-intervention period.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~outcomes are assessed in a two-month post-intervention period.

This trial's timeline: 3 weeks for screening, Varies for treatment, and outcomes are assessed in a two-month post-intervention period. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of participants with a Medication Health Center visit

Secondary study objectives

Number of participants with a Naloxone dispensing

Number of participants with a Prescription Drug Monitoring Program (PDMP) review

Number of participants with a Urine Drug Screens completed

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: MHC Early Outreach InterventionExperimental Treatment1 Intervention

Early implementation of a MHC outreach intervention program. Clinics in the early outreach intervention arm will be assigned to the MHC Direct patient outreach, where MHC staff will encourage patients to schedule an appointment with the MHC and primary care (PC) staff will be educated to encourage MHC visits.

Group II: MHC Delayed Outreach InterventionActive Control1 Intervention

Clinics in the usual care/delayed intervention arm will deliver usual care through the health plan, pharmacy and clinicians. As part of usual care, patients at these clinics can access naloxone through physician prescription or standing orders.

0 / 1Eligibility criteria met